Literature DB >> 4079279

Caffeine elimination: a test of liver function.

T Wang, G Kleber, F Stellaard, G Paumgartner.   

Abstract

Fasting plasma caffeine concentration and various parameters of caffeine elimination from plasma obtained after a standardized oral dose of 140 mg caffeine have been compared in nine patients with liver cirrhosis, eight patients with non-cirrhotic liver disease and ten healthy volunteers with regard to their ability to discriminate between the different groups. Fasting plasma caffeine concentrations were significantly higher in cirrhotics (11.1 +/- 10.5 mumol/l) than in healthy volunteers (1.5 +/- 0.8 mumol/l). The respective values measured in patients with non-cirrhotic liver disease (3.1 +/- 3.1 mumol/l) did not differ significantly from the controls. Plasma disappearance rate and clearance of caffeine were significantly decreased in cirrhotics (0.11 +/- 0.02 h-1; 1.0 +/- 0.3 ml/min per kg) and in patients with non-cirrhotic liver disease (0.18 +/- 0.04 h-1; 2.2 +/- 0.7 ml/min per kg) as compared to healthy volunteers (0.23 +/- 0.04 h-1; 3.1 +/- 0.9 ml/min per kg). Plasma caffeine concentration determined 12 h after administration of the test dosage discriminated best between patients with cirrhosis (5.4 +/- 1.6 mumol/l), patients with non-cirrhotic liver disease (2.0 +/- 1.4 mumol/l) and healthy volunteers (0.8 +/- 0.2 mumol/l). These results, the safety of the test compound and the simplicity of a single caffeine determination in plasma 12 h after a standardized dose of caffeine make this test attractive for evaluation of liver function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4079279     DOI: 10.1007/BF02291094

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  10 in total

1.  The handling of indocyanine green by the liver.

Authors:  G Paumgartner
Journal:  Schweiz Med Wochenschr       Date:  1975

2.  Clearance of antipyrine-dependence of quantitative liver function.

Authors:  P B Andreasen; L Ranek; B E Statland; N Tygstrup
Journal:  Eur J Clin Invest       Date:  1974-04       Impact factor: 4.686

3.  [Caffeine--an ubiquitous indicator of liver function].

Authors:  E Renner; A Wahländer; P Huguenin; H Wietholtz; R Preisig
Journal:  Schweiz Med Wochenschr       Date:  1983-08-09

4.  Determination of the hepatic elimination capacity (Lm) of galactose by single injection.

Authors:  N Tygstrup
Journal:  Scand J Clin Lab Invest Suppl       Date:  1966

5.  Caffeine: a model compound for measuring liver function.

Authors:  E Renner; H Wietholtz; P Huguenin; M J Arnaud; R Preisig
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

6.  Impaired elimination of caffeine in cirrhosis.

Authors:  P V Desmond; R V Patwardhan; R F Johnson; S Schenker
Journal:  Dig Dis Sci       Date:  1980-03       Impact factor: 3.199

7.  Aminopyrine demethylation measured by breath analysis in cirrhosis.

Authors:  J Bircher; A Küpfer; I Gikalov; R Preisig
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

8.  Portal-systemic spill-over of bile acids: a study of mechanisms using ursodeoxycholic acid.

Authors:  G Miescher; G Paumgartner; R Preisig
Journal:  Eur J Clin Invest       Date:  1983-12       Impact factor: 4.686

9.  A new look at the plasma disappearance of sulfobromophthalein (BSP): correlation with the BSP transport maximum and the hepatic plasma flow in man.

Authors:  W Häcki; J Bircher; R Preisig
Journal:  J Lab Clin Med       Date:  1976-12

10.  Evaluation of caffeine plasma levels by an automated enzyme immunoassay (EMIT) in comparison with a high-performance liquid chromatographic method.

Authors:  T Zysset; A Wahlländer; R Preisig
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

  10 in total
  6 in total

1.  The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.

Authors:  N R Scott; D Stambuk; J Chakraborty; V Marks; M Y Morgan
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

2.  Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers.

Authors:  M N Muscará; J Pedrazzoli; E L Miranda; J G Ferraz; E Hofstätter; G Leite; A F Magalhães; S Leonardi; G De Nucci
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

3.  Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

Authors:  C M da Silva; F L David; M N Muscará; S S Sousa; J G Ferraz; G de Nucci; N C Polimeno; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

4.  Correlation of caffeine elimination and Child's classification in liver cirrhosis.

Authors:  A Holstege; M Staiger; K Haag; W Gerok
Journal:  Klin Wochenschr       Date:  1989-01-04

5.  PK-DB: pharmacokinetics database for individualized and stratified computational modeling.

Authors:  Jan Grzegorzewski; Janosch Brandhorst; Kathleen Green; Dimitra Eleftheriadou; Yannick Duport; Florian Barthorscht; Adrian Köller; Danny Yu Jia Ke; Sara De Angelis; Matthias König
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

Review 6.  Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing.

Authors:  Jan Grzegorzewski; Florian Bartsch; Adrian Köller; Matthias König
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.